Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Musti Group Plc - Managers' transactions - Mäkipeura

Musti Group plc           Managers’ transactions                 2 February 2024 at 6.00pm Musti Group Plc - Managers' transactions - Mäkipeura ____________________________________________ Person subject to the notification requirement Name: Petri Mäkipeura Position: Closely associated person (1):Person Discharging Managerial Responsibilities In Issuer Name: Annamaija Hujala Position: Other senior manager Issuer: Musti Group plc LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL NOTIFICATION Reference number: 51151/4/4 ________________________________

Musti Group Plc - Managers' transactions - Rannikko

Musti Group plc           Managers’ transactions                 2 February 2024 at 6.00pm Musti Group Plc - Managers' transactions - Rannikko ____________________________________________ Person subject to the notification requirement Name: Toni Rannikko Position: Chief Financial Officer Issuer: Musti Group Plc LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL NOTIFICATION Reference number: 51184/4/4 ____________________________________________ Transaction date: 2024-02-01 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN:

Musti Group Plc - Managers' transactions - Tanner

Musti Group plc           Managers’ transactions                 2 February 2024 at 6.00pm Musti Group Plc - Managers' transactions - Tanner ____________________________________________ Person subject to the notification requirement Name: Sami Tanner Position: Other senior manager Issuer: Musti Group plc LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL NOTIFICATION Reference number: 51319/5/4 ____________________________________________ Transaction date: 2024-02-01 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000410758

Musti Group Plc - Managers' transactions – Tanner Advisory Oy

Musti Group plc           Managers’ transactions                 2 February 2024 at 6.00pm Musti Group Plc - Managers' transactions – Tanner Advisory Oy ____________________________________________ Person subject to the notification requirement Name: Tanner Advisory Oy Position: Closely associated person (X) Legal person  (1):Person Discharging Managerial Responsibilities In Issuer Person subject to the notification requirement Name: Sami Tanner Position: Other senior manager Issuer: Musti Group plc LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL

Musti Group Plc - Managers' transactions - Martin-Löf

Musti Group plc           Managers’ transactions                 2 February 2024 at 6.00pm Musti Group Plc - Managers' transactions - Martin-Löf ____________________________________________ Person subject to the notification requirement Name: Nanna Martin-Löf Position: Other senior manager Issuer: Musti Group plc LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL NOTIFICATION Reference number: 51365/5/4 ____________________________________________ Transaction date: 2024-02-01 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN:

Musti Group Plc - Managers' transactions - Nygren

Musti Group plc           Managers’ transactions                 2 February 2024 at 6.00pm Musti Group Plc - Managers' transactions - Nygren ____________________________________________ Person subject to the notification requirement Name: Malin Nygren Position: Other senior manager Issuer: Musti Group plc LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL NOTIFICATION Reference number: 51410/4/4 ____________________________________________ Transaction date: 2024-02-01 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000410758

Musti Group Plc - Managers' transactions - Nilsson

Musti Group plc           Managers’ transactions                 2 February 2024 at 6.00pm Musti Group Plc - Managers' transactions - Nilsson ____________________________________________ Person subject to the notification requirement Name: Ellinor Nilsson Position: Other senior manager Issuer: Musti Group plc LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL NOTIFICATION Reference number: 51389/6/8 ____________________________________________ Transaction date: 2024-02-02 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI4000410758

Musti Group Plc - Managers' transactions - Pettersson

Musti Group plc           Managers’ transactions                 2 February 2024 at 6.00pm Musti Group Plc - Managers' transactions - Pettersson ____________________________________________ Person subject to the notification requirement Name: Daniel Pettersson Position: Other senior manager Issuer: Musti Group plc LEI: 743700IE9NQGF9YZAI97 Notification type: INITIAL NOTIFICATION Reference number: 743700IE9NQGF9YZAI97_20240202071707_18 ____________________________________________ Transaction date: 2024-02-01 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument

DNB Bank ASA – status of share buy-back programme after week 5 2024

On 22 December 2023, DNB Bank ASA (“DNB”) announced that the company has decided to initiate a share buy-back programme comprising up to 0.75 percent of the company’s own shares, which represents a total of 11 569 599 shares. Up to 7 635 935 shares will be purchased on trading venues by 8 March 2024, and a proposal to cancel the shares will be made at the Annual General Meeting in 2024. At the same meeting it will also be proposed to redeem the remaining shares – up to 3 933 664 shares – from the Norwegian Government, represented by the Ministry of Trade, Industry and Fisheries (“NFD”),

Audientes A/S: Employment of CFO ends

Company Announcement no. 5-2024 February 2, 2024     Audientes A/S ("Audientes" or the "Company"), CVR 36047631, announces that the current CFO Troels Torp is ending his employment with the Company as of today.   Troels will continue to support the Company on a part-time basis as an independent consultant, assisting with financial reporting, management, etc.       For further information, please contact: Steen Thygesen, CEO, Audientes A/S Phone: +45 53 17 26 10 Email: st@audientes.com     About Audientes A/S Audientes A/S is a Danish hearing

Minutes from Extraordinary General Meeting in Akobo Minerals

2024-02-01 14.00:15.00 The shareholders of Akobo Minerals AB (publ) ("Akobo" or the "Company") have held an Extraordinary General Meeting on 2 February 2024 (the "EGM") whereby the following main decisions were made.Authorization The EGM resolved to authorize the Board of Directors to, with deviation from the shareholders' preferential rights, until the time of the next Annual General Meeting, on one or more occasions, resolve to issue new shares. Payment can be made against cash payment and / or through payment in kind and / or through set-off. Issue in accordance with the

NRC Group ASA - Appointed to major rail contract in Norway - NOK 436 million

Bane Nor has appointed NRC Norge AS, a company wholly owned by NRC Group ASA, to a contract for rehabilitation and upgrading of the catenary infrastructure on the railway between Hønefoss and Nesbyen.  The contract is appointed to a joint venture together with Nettpartner, and NRC’s share is valued at approximately NOK 436 million. The contract will involve rail services such as electro, signal/telecom, track and groundwork. The work will commence in March 2024 and is scheduled for completion in autumn 2027. Closing date for submission of complaints is 10 days from today, and formal

Cereno Scientific, a clinical stage biotech with an innovative portfolio in common and rare CVD, appoints Julia Fransson as Director of Business Development

Cereno Scientific (Nasdaq First North: CRNO B) today announced that Julia Fransson has joined the company as Director of Business Development. She joins the clinical stage biotech at an exciting point of the company’s growth journey, in developing innovative treatments for common and rare cardiovascular disease, with lead candidate drug CS1 in phase II in orphan disease PAH which is to deliver top line study results by Q2 this year.“As our innovative portfolio of candidate drugs are progressing well, we need to scale our capacity on the business development side of our operations. Julia

The Nomination Committee's proposal regarding the Board of Directors of Humana for the 2024 AGM

Ahead of the Annual General Meeting 2024, The Nomination Committee proposes that the Board of Directors, for the period until the end of the next AGM, shall consist of seven members elected by the Annual General Meeting without alternates.Humana's Nomination Committee prior to the 2024 AGM consists of Fredrik Strömholm, appointed by Impilo Care AB (Chairman of the Nomination Committee), Alexander Kopp, appointed by Incentive AS, Richard Torgerson, appointed by Nordea Funds, Anette Andersson, appointed by SEB Investment Management AB and Anders Nyberg, Humana’s Chairman of the Board.

Comment from the Board of Directors of Biokraft International AB (publ) about the mandatory tender offer from 1Vision Biogas

1Vision Biogas AB (“1Vision Biogas”) has today announced a mandatory cash tender offer for the shares in Biokraft International AB (publ), reg.no 556528-4733 (“Biokraft” or the “Company”) at a price of SEK 20.65 per share (the “Offer”). The Offer is made due to 1Vision Biogas’ shareholding in Biokraft, following Aneo Renewables Holding AS and St1 Sverige AB consolidated their respective shareholding in Biokraft into the newly established and jointly owned company 1Vision Biogas, which now corresponds to approximately 55 per cent of the total number of shares and votes in the Company.

UPM-Kymmene Corporation: Managers’ Transactions (Manner)

UPM-Kymmene Corporation                Managers’ Transactions                        2 February 2024 at 16:15 EET UPM-Kymmene Corporation: Managers’ Transactions (Manner) UPM-Kymmene Corporation has on 2 February 2024 received the following notification: ____________________________________________Person subject to the notification requirementName: Topi MannerPosition: Member of the BoardIssuer: UPM-Kymmene CorporationLEI: 213800EC6PW5VU4J9U64Notification type: INITIAL NOTIFICATION____________________________________________Transaction date: 2024-02-02Venue:

Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform

STOCKHOLM, Sweden, 2 February 2024 – Impilo has closed its investment in Avia Pharma Holding AB (“Avia” or the “Company”), a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Continuing on Impilo’s long-term ambitions of building a leading Northern European OTC/Rx platform, and the work through Mallax, Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth. Avia was founded in 2016 and focuses on medically positioned products

#24-10 Unit issue in Eurobattery Minerals AB

Information regarding the last day of trading in paid subscribed units and the first day of trading in warrants issued by Eurobattery Minerals AB The unit issue in Eurobattery Minerals AB (“The Company”) is now registered with the Swedish Companies Registration Office and the last day of trading in paid subscribed units has been set for February 7, 2024.   The first day of trading for the Company’s warrants series 4 and 5 (TO4 and TO5) has been set for February 13, 2024.   Information regarding the affected instruments:   Listing name: Eurobattery Minerals BTU

CS MEDICA A/S Achieves New Milestone with Patent on their Wound Care Treatment.

CS MEDICA received its third-issued patent on its "Wound Gel," offering an advanced healing process for wounds such as minor abrasions, cuts, burns, and sunburns.CS MEDICA A/S ("CS MEDICA" or "The Company"), an innovator in the healthcare industry, is proud to announce the recent patent approval for its Wound Gel, marked by the Danish Patent and Trademark Office under patent number DK 181458.  This achievement is the third patent granted to CS MEDICA in the past year, reinforcing the company's commitment to innovation in healthcare. Moreover, the company has advanced its research and

SAGAX INVESTS SEK 692 MILLION THROUGH 7 TRANSACTIONS

Sagax has through 7 separate transactions acquired 8 properties for the equivalent of SEK 692 million. The properties comprise a lettable area of 55,400 square metres and 117,100 square metres of land, whereof 29,000 square metres leasehold. The annual rental income amounts to the equivalent of SEK 81 million. The occupancy rate is 99% and the average remaining lease term is 9.2 years. Closing for the equivalent of SEK 599 million has taken place during the first quarter of 2024. Closing for the remaining SEK 93 million is expected to take place during the end of the first quarter of

Allgon Export opens its doors to new partners

Continuing Allgon’s plan to consolidate its resources into a single and stronger force, Tele Radio Export has been transformed into Allgon Export. The subsidiary will continue with strategic expansion into new markets, now with the full product lines of both subsidiary brands, Tele Radio and Åkerströms. Operations under the new organization officially begin in February 1[st], 2024.Pär Wahlstrand resumes his role under this new brand name as the General Manager of Allgon Export, based in the same location in Gothenburg. With over 15 years of experience in business development and 7 within

Norse Atlantic ASA: New share capital registered

Arendal, 2 February 2024: Reference is made to the stock exchange notice by Norse Atlantic ASA (the "Company") on 25 January 2024 regarding the final results of subsequent offering and allocation of new shares in the Company (the "Subsequent Offering"). The share capital increase pertaining to the issuance of the shares in the Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises: Share capital: NOK 642,619,200 Total number of shares: 128,523,840 Nominal value per share: NOK 5 For further information, please contact: Investors: CFO,

#24-09 Unit issue in Coegin Pharma AB

The board of Coegin Pharma AB (the “Company”) has decided on a unit issue with preferential rights for the Company’s existing shareholders subject to approval from an extra general meeting, to be held on February 5, 2024. The last day of trading in the Company’s shares including the right to receive unit rights is February 5, 2024. The first day of trading in the Company’s shares excluding the right to receive unit rights is February 6, 2024. The record date is February 7, 2024. The shareholders of the Company will receive seven (7) unit rights for each ten (10) shares held per the

Invitation to a Press Conference on Bittium Corporation’s Financial Statement Bulletin 2023

Bittium CorporationPress Release Invitation to a Press Conference on Bittium Corporation’s Financial Statement Bulletin 2023 Bittium Corporation’s Press Release on February 2, 2024, at 3.00 pm (CET+1) Bittium Corporation’s Financial Statement Bulletin 2023 will be published on Friday, February 9, 2024, at 8.00 am (CET+1). The release will be available on company’s website www.bittium.com immediately after the publication. Bittium will hold a webcast for media, analysts and institutional investors on Friday, February 9, 2024, at 9.00 am (CET+1). The webcast will be held in

There are no items matching the current filter
There are no more items matching the current filter
Back to top